Pharmacologic Management of Type 2 Myocardial Infarction: An Underdefined Frontier

Type 2 myocardial infarction (T2MI) results from myocardial oxygen supply–demand imbalance in the absence of acute atherothrombotic plaque rupture and is associated with substantial short- and long-term mortality. Although increasingly recognized with the widespread use of high-sensitivity cardiac troponin assays, optimal pharmacologic management of T2MI remains poorly defined. We performed a narrative review evaluating pharmacologic treatment patterns and outcomes in adults with adjudicated or clinically coded T2MI. Evidence consistently demonstrates a high prevalence of underlying coronary artery disease (CAD) in T2MI, with up to two-thirds of patients exhibiting significant coronary artery stenosis. Despite this overlap with ischemic heart disease, prescription rates of antiplatelet agents, statins, β-blockers, and renin–angiotensin–aldosterone system (RAAS) inhibitors are substantially lower in T2MI compared with T1MI. Observational data suggest that statins, β-blockers, RAAS inhibitors, and combination secondary prevention strategies may be associated with improved survival, whereas evidence supporting routine antiplatelet or anticoagulant therapy remains limited and inconsistent. Overall, T2MI represents a high-risk and underrecognized clinical entity for which pharmacologic management is largely extrapolated from T1MI and CAD. Prospective, T2MI-focused studies are urgently needed to define optimal secondary prevention strategies and improve clinical outcomes.